METHYLPREDNISOLONE ACETATE Drug Patent Profile
Which patents cover Methylprednisolone Acetate, and what generic alternatives are available?
Methylprednisolone Acetate is a drug marketed by Amneal, Caplin, Emerge Bioscience, Epic Pharma Llc, Eugia Pharma, Hikma, Ph Health, Sagent Pharms Inc, Sandoz, Teva Pharms Usa, Watson Labs, and Wilshire Pharms Inc. and is included in nineteen NDAs.
The generic ingredient in METHYLPREDNISOLONE ACETATE is methylprednisolone acetate. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the methylprednisolone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Methylprednisolone Acetate
A generic version of METHYLPREDNISOLONE ACETATE was approved as methylprednisolone acetate by EMERGE BIOSCIENCE on February 23rd, 2005.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for METHYLPREDNISOLONE ACETATE?
- What are the global sales for METHYLPREDNISOLONE ACETATE?
- What is Average Wholesale Price for METHYLPREDNISOLONE ACETATE?
Summary for METHYLPREDNISOLONE ACETATE
| US Patents: | 0 |
| Applicants: | 12 |
| NDAs: | 19 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 72 |
| Clinical Trials: | 41 |
| Patent Applications: | 5,197 |
| Drug Prices: | Drug price information for METHYLPREDNISOLONE ACETATE |
| DailyMed Link: | METHYLPREDNISOLONE ACETATE at DailyMed |
Recent Clinical Trials for METHYLPREDNISOLONE ACETATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Beijing Tiantan Hospital | PHASE3 |
| Menoufia University | N/A |
| Centre hospitalier de l'Université de Montréal (CHUM) | Phase 4 |
Pharmacology for METHYLPREDNISOLONE ACETATE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for METHYLPREDNISOLONE ACETATE
US Patents and Regulatory Information for METHYLPREDNISOLONE ACETATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wilshire Pharms Inc | METHYLPREDNISOLONE ACETATE | methylprednisolone acetate | INJECTABLE;INJECTION | 214870-001 | Jan 3, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Watson Labs | METHYLPREDNISOLONE ACETATE | methylprednisolone acetate | INJECTABLE;INJECTION | 085600-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Watson Labs | METHYLPREDNISOLONE ACETATE | methylprednisolone acetate | INJECTABLE;INJECTION | 085595-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Amneal | METHYLPREDNISOLONE ACETATE | methylprednisolone acetate | INJECTABLE;INJECTION | 210043-001 | May 20, 2019 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
